Indian Society of Gastroenterology consensus on ulcerative colitis

Indian Journal of Gastroenterology

Volumn 31, Issue 6, 2012, Pages 307-323

  Ramakrishna, Balakrishnan S ^a   Makharia, Govind K ^b   Abraham, Philip ^c   Ghoshal, Uday C ^d   Jayanthi, Venkataraman ^e   Agarwal, Brij Kishore ^f   Ahuja, Vineet ^b   Bhasin, Deepak K ^g   Bhatia, Shobna J ^h   Choudhuri, Gourdas ^d   Dadhich, Sunil ⁱ   Desai, Devendra C ^c   Dhali, Gopal Krishna ^j   Goswami, Bhaba Dev ^k   Issar, Sanjeev K ^l   Jain, Ajay K ^m   Kochhar, Rakesh ^g   Kumar, Ajay ⁿ   Loganathan, Goundappa ^o   Misra, Sri Prakash ^p   Pai, C Ganesh ^q   Pal, Sujoy ^b   Pulimood, Anna ^a   Puri, Amarender S ^r   Ramesh, Ganesh N ^s   Ray, Gautam ^t   Singh, Shivaram P ^u   Sood, Ajit ^v   Tandan, Manu ^w   more..

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c P D HINDUJA NATIONAL HOSPITAL   (India)

^d SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^e Global Health City   (India)

^f Consultant Gastroenterologist ^*  (India)

^g POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^h KEM HOSPITAL   (India)

ⁱ DR S N MEDICAL COLLEGE   (India)

^j INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^k Guwahati Medical College   (India)

^l Bhilai Steel Plant Hospital   (India)

^m CHOITHRAM HOSPITAL AND RESEARCH CENTRE   (India)

ⁿ INDRAPRASTHA APOLLO HOSPITAL   (India)

^o G L Hospital   (India)

^p MLN MEDICAL COLLEGE   (India)

^q KASTURBA MEDICAL COLLEGE   (India)

^r G B PANT HOSPITAL   (India)

^s Department of Gastrointestinal Surgery Digestive Disease Center   (India)

^t B R Singh Hospital   (India)

^u S C B Medical College   (India)

^v DAYANAND MEDICAL COLLEGE AND HOSPITAL   (India)

^w ASIAN INSTITUTE OF GASTROENTEROLOGY   (India)

more..

Author keywords

Complications; Diagnosis; Inflammatory bowel disease; Management

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOGLOBULIN M ANTIBODY; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PREDNISOLONE; PROBIOTIC AGENT; STEROID; THIOPURINE METHYLTRANSFERASE;

ALOPECIA; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CATARACT; CLINICAL FEATURE; CLINICAL PRACTICE; COLON BIOPSY; COLON DISEASE; COLONOSCOPY; CONSENSUS; CROHN DISEASE; CUSHINGOID SYNDROME; DAIRY PRODUCT; DATA PROCESSING; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG RESISTANCE; DYSPLASIA; ENDOSCOPY; FAMILY HISTORY; FECES ANALYSIS; FECES CULTURE; FEVER; FLUID RETENTION; GASTROENTEROLOGY; GLAUCOMA; HEALTH CARE COST; HEPATITIS; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPOKALEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INDIA; INFECTION; INTESTINE INFECTION; INTESTINE INJURY; LEUKOPENIA; LOW DRUG DOSE; MAINTENANCE THERAPY; MEDICAL HISTORY; MEDICAL SOCIETY; METABOLIC ALKALOSIS; METABOLIC BONE DISEASE; OSTEOPOROSIS; PANCREATITIS; PANCYTOPENIA; PATIENT ASSESSMENT; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PREGNANCY; PREVALENCE; PROCTOCOLECTOMY; PROGNOSIS; RASH; REMISSION; SCREENING TEST; SIDE EFFECT; STANDARDIZATION; STRIA; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT PLANNING; TUBERCULOSIS; ULCERATIVE COLITIS; WOUND HEALING IMPAIRMENT;

COLITIS, ULCERATIVE; DELPHI TECHNIQUE; GASTROENTEROLOGY; HUMANS; INDIA; SOCIETIES, MEDICAL;

EID: 84870298283     PISSN: 02548860     EISSN: 09750711     Source Type: Journal    
DOI: 10.1007/s12664-012-0259-0     Document Type: Article

References (154)

1. Makharia GK, Ramakrishna BS, Abraham P, et al. Survey of inflammatory bowel diseases in India. Indian J Gastroenterol. 2012; 31: doi: 10. 1007/s12664-012-0258-1.
2. Linstone H, Turoff M. The Delphi method: techniques and application. http://www. is. njit. edu/pubs/delphibook/. Accessed on August 15, 2012.
3. Periodic health examination: 2. 1984 update. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J. 1984; 130: 1278-85.
4. Loftus EV Jr,. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126: 1504-17.
5. Khosla SN, Girdhar NK, Lal S, Mishra DS. Epidemiology of ulcerative colitis and select general population of northern India. J Assoc Physicians India. 1986; 34: 405-7.
6. Sood A, Midha V, Sood N, et al. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut. 2003; 52: 1587-90.
7. Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis. 2008; 14: 542-9.
8. Lok KH, Hung HG, Ng CH, et al. Epidemiology and clinical characteristics of ulcerative colitis in Chinese population: experience from a single center in Hong Kong. J Gastroenterol Hepatol. 2008; 23: 406-10.
9. Chow DK, Leong RW, Tsoi KK, et al. Long-term follow-up of ulcerative colitis in the Chinese population. Am J Gastroenterol. 2009; 104: 647-54.
10. Morita N, Toki S, Hirohashi T, et al. Incidence and prevalence of inflammatory bowel disease in Japan: nationwide epidemiological survey during the year 1991. J Gastroenterol. 1995; 30 Suppl 8: 1-4.
11. Lee YM, Fock K, See SJ, Ng TM, Khor C, Teo EK. Racial differences in the prevalence of ulcerative colitis and Crohn's disease in Singapore. J Gastroenterol Hepatol. 2000; 15: 622-5.
12. Ling KL, Ooi CJ, Luman W, Cheong WK, Choen FS, Ng HS. Clinical characteristics of ulcerative colitis in Singapore, a multiracial city-state. J Clin Gastroenterol. 2002; 35: 144-8.
13. Tan YM, Goh KL. Ulcerative colitis in a multiracial Asian country: racial differences and clinical presentation among Malaysian patients. World J Gastroenterol. 2005; 11: 5859-62.
14. Probert CS, Mayberry JF, Mann R. Inflammatory bowel disease in the rural Indian subcontinent: a survey of patients attending mission hospitals. Digestion. 1990; 47: 42-6.
15. Maroo MK, Nag NK, Sortur SV, Patil RS. Ulcerative colitis in Southern Maharashtra. J Indian Med Assoc. 1974; 63: 350-4.
16. Tandon BN, Mathur AK, Mohapatra LN, Tandon HD, Wig KL. A study of the prevalence and clinical pattern of non-specific ulcerative colitis in northern India. Gut. 1965; 6: 448-53.
17. Sood A, Midha V. Epidemiology of inflammatory bowel disease in Asia. Indian J Gastroenterol. 2007; 26: 285-9.
18. Satsangi J, Jewell DP, Rosenberg WM, Bell JI. Genetics of inflammatory bowel disease. Gut. 1994; 35: 696-700.
19. Jiang L, Xia B, Li J, et al. Risk factors for ulcerative colitis in a Chinese population: an age-matched and sex-matched case-control study. J Clin Gastroenterol. 2007; 41: 280-4.
20. Kitahora T, Utsunomiya T, Yokota A. Epidemiological study of ulcerative colitis in Japan: incidence and familial occurrence. The Epidemiology Group of the Research Committee of Inflammatory Bowel Disease in Japan. J Gastroenterol. 1995; 30 Suppl 8: 5-8.
21. Park JB, Yang SK, Byeon JS, et al. Familial occurrence of inflammatory bowel disease in Korea. Inflamm Bowel Dis. 2006; 12: 1146-51.
22. Probert CS, Jayanthi V, Hughes AO, Thompson JR, Wicks AC, Mayberry JF. Prevalence and family risk of ulcerative colitis and Crohn's disease: an epidemiological study among Europeans and south Asians in Leicestershire. Gut. 1993; 34: 1547-51.
23. Probert CS, Jayanthi V, Pinder D, et al. Epidemiological study of ulcerative proctocolitis in Indian migrants and the indigenous population of Leicestershire. Gut. 1992; 33: 687-93.
24. Carr I, Mayberry JF. The effects of migration on ulcerative colitis: a three-year prospective study among Europeans and first and second-generation South Asians in Leicester (1991-1994). Am J Gastroenterol. 1999; 94: 2918-22.
25. Jayanthi V, Probert CS, Pollock DJ, et al. Low incidence of ulcerative colitis and proctitis in Bangladeshi migrants in Britain. Digestion. 1992; 52: 34-42.
26. Probert CS, Jayanthi V, Mayberry JF. Inflammatory bowel disease in Indian migrants in Fiji. Digestion. 1991; 50: 82-4.
27. Rajput HI, Seebaran AR, Desai Y. Ulcerative colitis in the Indian population of Durban. S Afr Med J. 1992; 81: 245-8.
28. Kochhar R, Mehta SK, Nagi B, Bhatia V, Goenka MA, Malik AK. Extraintestinal manifestations in idiopathic ulcerative colitis. Indian J Gastroenterol. 1991; 10: 88-9.
29. Pokharna RK, Kabra PK, Sharma P, Kochar DK. Extraintestinal manifestations of idiopatic ulcerative colitis in north western India. Indian J Gastroenterol. 2004; 123: 89-90.
30. Chandrasekaran AN, Porkodi R, Madhavan R, Sambandam PR, Jayanthi V, Ramathilagam B. Spectrum of clinical and immunological features of systemic rheumatic disorders in a referral hospital in south India: arthritis in ulcerative colitis. J Indian Rheumat Assoc. 1995; 3: 43-7.
31. Habeeb MA, Rajalingam R, Dhar A, Kumar A, Sharma MP, Mehra NK. HLA association and occurrence of autoantibodies in Asian patients with ulcerative colitis. Am J Gastroenterol. 1997; 92: 772-6.
32. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology. Practice Parameters Committee. Am J Gastroenterol. 2004; 99: 1371-85.
33. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004; 53 Suppl 5: V1-16.
34. Stange EF, Travis SP, Vermeire S, et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn's Colitis. 2008; 2: 1-23.
35. Ooi CJ, Fock KM, Makharia GK, et al. The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol. 2010; 25: 453-68.
36. Tedesco FJ, Hardin RD, Harper RN, Edwards BH. Infectious colitis endoscopically simulating inflammatory bowel disease: a prospective evaluation. Gastrointest Endosc. 1983; 29: 195-7.
37. Dunzendorfer T, Kasznica J. Amebic and/or ulcerative colitis? Gastrointest Endosc. 1998; 48: 450-1.
38. Misra SP, Misra V, Dwivedi M, Singh PA. Colonic tuberculosis mimicking ulcerative colitis. J Assoc Physicians India. 1998; 46: 309-10.
39. Chodos JE. Campylobacter infection mimicking ulcerative colitis. NY State J Med. 1986; 86: 22-3.
40. Ibrahim TM, Iheonunekwu N, Gill V, Vantapool H. Differentiating amoebic ulcero-haemorrhagic recto-colitis from idiopathic inflammatory bowel disease: still a diagnostic dilemma. West Indian Med J. 2005; 54: 210-12.
41. Mann EA, Saeed SA. Gastrointestinal infection as a trigger for inflammatory bowel disease. Curr Opin Gastroenterol. 2012; 28: 24-9.
42. Khuroo MS, Mahajan R, Zargar SA, et al. The colon in shigellosis: serial colonoscopic appearances in Shigella dysenteriae I. Endoscopy. 1990; 22: 35-8.
43. Kochhar R, Ayyagari A, Goenka MK, Dhali GK, Aggarwal R, Mehta SK. Role of infectious agents in exacerbations of ulcerative colitis in India. A study of Clostridium difficile. J Clin Gastroenterol. 1993; 16: 26-30.
44. Kishore J, Ghoshal U, Ghoshal UC, et al. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol. 2004; 53: 1155-60.
45. Banerjee D, Deb R, Dar L, et al. High frequency of parasitic and viral stool pathogens in patients with active ulcerative colitis: report from a tropical country. Scand J Gastroenterol. 2009; 44: 325-31.
46. Roblin X, Pillet S, Oussalah A, et al. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol. 2011; 106: 2001-8.
47. Vaishnavi C, Kochhar R, Bhasin D, Thennarasu K, Singh K. Simultaneous assays for Clostridium difficile and faecal lactoferrin in ulcerative colitis. Trop Gastroenterol. 2003; 24: 13-6.
48. Kashyap B, Sinha S, Das S, Rustagi N, Jhamb R. Efficiency of diagnostic methods for correlation between prevalence of enteric protozoan parasites and HIV/AIDS status--an experience of a tertiary care hospital in East Delhi. J Parasit Dis. 2010; 34: 63-7.
49. Montes M, Sawhney C, Barros N. Strongyloides stercoralis: there but not seen. Curr Opin Infect Dis. 2010; 23: 500-4.
50. Navarro-Llavat M, Domènech E, Bernal I, et al. Prospective, observational, cross-sectional study of intestinal infections among acutely active inflammatory bowel disease patients. Digestion. 2009; 80: 25-9.
51. Vaishnavi C. Clostridium difficile infection: clinical spectrum and approach to management. Indian J Gastroenterol. 2011; 30: 245-54.
52. Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? Inflamm Bowel Dis. 2010; 16: 1620-7.
53. Sung JJY, Kamm MA, Marteau P. Asian perspectives in the management of inflammatory bowel disease: findings from a recent survey. J Gastroenterol Hepatol. 2010; 25: 183-93.
54. Schusselé Filliettaz S, Juillerat P, Burnand B, et al. Appropriateness of colonoscopy in Europe (EPAGE II). Chronic diarrhea and known inflammatory bowel disease. Endoscopy. 2009; 41: 218-26.
55. Louis E, Belaiche J, Reenaers C. Do clinical factors help to predict disease course in inflammatory bowel disease? World J Gastroenterol. 2010; 16: 2600-3.
56. Regueiro M, Loftus EV, Steinhart AH, Cohen RD. Medical management of left-sided ulcerative colitis and ulcerative proctitis: Critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006; 12: 979-94.
57. Kochhar R, Goenka MK, Kaushik SP, Gupta NM, Nagi B, Mehta SK. Colorectal carcinoma in Indian patients with idiopathic ulcerative colitis. Eur J Cancer Prev. 1992; 1: 293-6.
58. Venkataraman S, Mohan V, Ramakrishna BS, et al. Risk of colorectal cancer in ulcerative colitis in India. J Gastroenterol Hepatol. 2005; 20: 705-9.
59. Regueiro M, Rodemann J, Kip KE, et al. Physician assessment of ulcerative colitis activity correlates poorly with endoscopic disease activity. Inflamm Bowel Dis. 2011; 17: 1008-14.
60. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55: 749-53.
61. Naber AHJ, de Jong DJ. Assessment of disease activity in inflammatory bowel disease; relevance for clinical trials. Neth J Med. 2003; 61: 105-10.
62. Thia KT, Loftus EV Jr, Pardi DS, et al. Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm Bowel Dis. 2011; 17: 1257-64.
63. Bhatt J, Patil S, Joshi A, Abraham P, Desai D. Self-reported treatment adherence in inflammatory bowel disease in Indian patients. Indian J Gastroenterol. 2009; 28: 143-6.
64. Gionchetti P, Rizzello F, Morselli C, Tambasco R, Campieri M. Review article: aminosalicylates for distal colitis. Aliment Pharmacol Ther. 2006; 24 Suppl 3: 41-4.
65. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000; 95: 1263-76.
66. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997; 40: 775-81.
67. Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;(1): CD004115.
68. Campieri M, De Franchis R, Bianchi Porro G, et al. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Scand J Gastroenterol. 1990; 25: 663-8.
69. D'Arienzo A, Panarese A, D'Armiento FP, et al. 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. Am J Gastroenterol. 1990; 85: 1079-82.
70. Hanauer SB. Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The US PENTASA Enema Study Group. Inflamm Bowel Dis. 1998; 4: 79-83.
71. Biddle WL, Greenberger NJ, Swan JT, et al. 5-Aminosalicylic acid enemas: effective agent in maintaining remission in left -sided ulcerative colitis. Gastroenterology. 1988; 94: 1075-9.
72. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2): D000544.
73. Baron JH, Connell AM, Lennard-Jones JE, et al. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet. 1962; 1: 1094-6.
74. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2): CD000543.
75. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2009; 15: 1-8.
76. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008; 57: 893-902.
77. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997; 92: 1867-71.
78. Faubion Jr WA, Loftus Jr EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001; 121: 255-60.
79. Truelove SC, Watkinson G, Draper G. Comparison of corticosteroid and SASP therapy in ulcerative colitis. Br Med J. 1962; 2: 1708-11.
80. Lennard-Jones JE, Longmore AJ, Newell AC, Wilson CWE, Avery Jones F. An assessment of prednisone, Salazopyrin and topicalhydrocortisone hemisuccinate used as outpatient treatment for ulcerative colitis. Gut. 1960; 1: 217-22.
81. Baron JH, Connell AM, Kanaghinis TG, et al. Outpatient treatment of ulcerative colitis: comparison between three doses of oral prednisone. Br Med J. 1962; 2: 441-3.
82. Rosenberg W, Ireland A, Jewell DP. High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol. 1990; 12: 40-1.
83. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006; 130: 940-87.
84. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet. 1974; i: 1067-70.
85. Turner D, Walsh C, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007; 5: 103-10.
86. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006; 55: 47-53.
87. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;(1): CD000478.
88. Etchevers MJ, Aceituno M, Sans M. Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. World J Gastroenterol. 2008; 14: 5512-8.
89. Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol. 1990; 85: 717-22.
90. Leung Y, Panaccione R, Hemmelgarn B, Jones J. Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis. Dig Dis Sci. 2008; 53: 1455-61.
91. Sood A, Kaushal V, Midha V, Bhatia KL, Sood N, Malhotra V. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol. 2002; 37: 270-4.
92. Hibi T, Naganuma M, Kitahora T, Kinjyo F, Shimoyama T. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol. 2003; 38: 740-6.
93. Sood A, Midha V, Sood N, Avasthi G. Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis. Indian J Gastroenterol. 2003; 22: 79-81.
94. Sood A, Midha V, Sood N, Bansal M. Long term results of use of azathioprine in patients with ulcerative colitis in India. World J Gastroenterol. 2006; 12: 7332-6.
95. Lichtenstein GR. Use of laboratory testing to guide 6-mercaptopurine/azathioprine therapy. Gastroenterology. 2004; 127: 1558-64.
96. Desire S, Balasubramanian P, Bajel A, et al. Frequency of TPMT alleles in Indian patients with acute lymphatic leukemia and effect on the dose of 6-mercaptopurine. Med Oncol. 2010; 27: 1046-9.
97. Kham SK, Tan PL, Tay AH, Heng CK, Yeoh AE, Quah TC. Thiopurine methyltransferase polymorphisms in a multiracial Asian population and children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2002; 24: 353-9.
98. Ashavaid TF, Raghavan R, Shah S, Kapadia A, Almel S, Desai D. TPMT and DPD polymorphisms: efficient screening method for Indian patients considering taking thiopurine and 5-FU drugs. Dis Markers. 2009; 27: 231-8.
99. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994; 330: 1841-5.
100. van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003; 125: 1025-31.
101. Sood A, Midha V, Sood N, et al. Cyclosporine in the treatment of severe steroid refractory ulcerative colitis: a retrospective analysis of 24 cases. Indian J Gastroenterol. 2008; 27: 232-5.
102. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(3): CD005112.
103. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462-76.
104. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011; 60: 571-607.
105. Nordgaard-Lassen I, Dahlerup JF, Belard E, et al. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J. 2012; 59: C4480.
106. Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol. 2006; 12: 974-6.
107. Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm Bowel Dis. 2007; 13: 1453-4.
108. Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat. 2008; 15: 89-102.
109. Viazis N, Vlachogiannakos J, Georgiou O, et al. Course of inflammatory bowel disease in patients infected with human immunodeficiency virus. Inflamm Bowel Dis. 2010; 16: 507-11.
110. Shale MJ, Seow CH, Coffin CS, Kaplan GG, Panaccione R, Ghosh S. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther. 2010; 31: 20-34.
111. Wilckens V, Kannengiesser K, Hoxhold K, Frenkel C, Kucharzik T, Maaser C. The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelines. Scand J Gastroenterol. 2011; 46: 855-61.
112. Pal S, Sahni P, Pande GK, Acharya SK, Chattopadhyay TK. Outcome following emergency surgery for refractory severe ulcerative colitis in a tertiary care centre in India. BMC Gastroenterol. 2005; 5: 39.
113. Cima RR. Timing and indications for colectomy in chronic ulcerative colitis: Surgical consideration. Dig Dis. 2010; 28: 501-7.
114. van Assche G, Vermeire S, Rutgeerts P. Management of acute severe ulcerative colitis. Gut. 2011; 60: 130-3.
115. Travis S, Satsangi J, Lémann M. Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers. Gut. 2011; 60: 3-9.
116. Randall J, Singh B, Warren BF, Travis SP, Mortensen NJ, George BD. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg. 2010; 97: 404-9.
117. Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007; 204: 956-62.
118. Koltun WA. Role of medical rescue therapy in the management of acute severe ulcerative colitis: the surgical perspective. Expert Rev Gastroenterol Hepatol. 2009; 3: 325-7.
119. Andersson P, Söderholm JD. Surgery in ulcerative colitis: indication and timing. Dig Dis. 2009; 27: 335-40.
120. Rao YG, Saxena R, Sahni P, Pande GK, Chattopadhyay TK. Functional outcome and patient satisfaction after ileal pouch anal anastomosis for ulcerative colitis in a developing country. Trop Gastroenterol. 2002; 23: 66-9.
121. Somashekar U, Gupta S, Soin A, Nundy S. Functional outcome and quality of life following restorative proctocolectomy for ulcerative colitis in Indians. Int J Colorectal Dis. 2010; 25: 967-73.
122. Odze RD. Adenomas and adenoma-like DALMs in chronic ulcerative colitis: a clinical, pathological, and molecular review. Am J Gastroenterol. 1999; 94: 1746-50.
123. Vleggaar FP, Lutgens MW, Claessen MM. Review article: the relevance of surveillance endoscopy in long-lasting inflammatory bowel disease. Aliment Pharmacol Ther. 2007; 26 Suppl 2: 47-52.
124. Thomas T, Nair P, Dronfield MW, Mayberry JF. Management of low and high-grade dysplasia in inflammatory bowel disease: the gastroenterologists' perspective and current practice in the United Kingdom. Eur J Gastroenterol Hepatol. 2005; 17: 1317-24.
125. Eaden JA, Mayberry JF. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut. 2002; 51 Suppl 5: V10-12.
126. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003; 124: 795-841.
127. Loftus EV Jr, Achenbach SJ, Sandborn WJ, Tremaine WJ, Oberg AL, Melton LJ 3rd. Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2003; 1: 465-73.
128. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16, 416 patients in Denmark. Am J Epidemiol. 2002; 156: 1-10.
129. Ezzat Y, Hamdy K. The frequency of low bone mineral density and its associated risk factors in patients with inflammatory bowel diseases. Int J Rheum Dis. 2010; 13: 259-65.
130. Navaneethan U, Shen L, Venkatesh PG, et al. Influence of ileal pouch anal anastomosis on bone loss in ulcerative colitis patients. J Crohns Colitis. 2011; 5: 415-22.
131. Shen B, Remzi FH, Oikonomou IK, et al. Risk factors for low bone mass in patients with ulcerative colitis following ileal pouch-anal anastomosis. Am J Gastroenterol. 2009; 104: 639-46.
132. Khadgawat R, Makharia GK, Puri K. Evaluation of bone mineral density among patients with inflammatory bowel disease in a tertiary care setting in India. Indian J Gastroenterol. 2008; 27: 103-6.
133. Jowett SL, Seal CJ, Phillips E, Gregory W, Barton JR, Welfare MR. Dietary beliefs of people with ulcerative colitis and their effect on relapse and nutrient intake. Clin Nutr. 2004; 23: 161-70.
134. Bernstein CN, Ament M, Artinian L, Ridgeway J, Shanahan F. Milk tolerance in adults with ulcerative colitis. Am J Gastroenterol. 1994; 89: 872-7.
135. Chaves S, Perdigon G, de Moreno de LeBlanc A. Yoghurt consumption regulates the immune cells implicated in acute intestinal inflammation and prevents the recurrence of the inflammatory process in a mouse model. J Food Prot. 2011; 74: 801-11.
136. Elahi B, Nikfar S, Derakhshani S, Vafaie M, Abdollahi M. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig Dis Sci. 2008; 53: 1278-84.
137. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999; 354: 635-9.
138. Mallon P, McKay D, Kirk S, Gardiner K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;(4): CD005573.
139. Do VT, Baird BG, Kockler DR. Probiotics for maintaining remission of ulcerative colitis in adults. Ann Pharmacother. 2010; 44: 565-71.
140. Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs. 2012; 72: 803-23.
141. Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2009; 7: 1202-9.
142. Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007; 56: 830-7.
143. Uribe M, Chavez-Tapia NC, Mendez-Sanchez N. Pregnancy and autoimmune hepatitis. Ann Hepatol. 2006; 5: 187-9.
144. Warrell DW, Taylor R. Outcome for the foetus of mothers receiving prednisolone during pregnancy. Lancet. 1968; 1: 117-8.
145. Ham M, Moss AC. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol. 2012; 5: 113-23.
146. Schirbel A, Sturm A. Imaging in inflammatory bowel disease: mucosal healing in ulcerative colitis: relevance for clinical outcomes. Curr Drug Targets. 2012; May 28. [Epub ahead of print].
147. Hanauer SB. Review article: the long-term management of ulcerative colitis. Aliment Pharmacol Ther. 2004; 20 Suppl 4: 97-101.
148. Stolfi C, Pellegrini R, Franze E, Pallone F, Monteleone G. Molecular basis of the potential of mesalazine to prevent colorectal cancer. World J Gastroenterol. 2008; 14: 4434-9.
149. Levine JS, Burakoff R. Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: current concepts. Inflamm Bowel Dis. 2007; 13: 1293-8.
150. Ullman T, Croog V, Harpaz N, et al. Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine. Clin Gastroenterol Hepatol. 2008; 6: 1225-30.
151. Bernstein CN, Nugent Z, Blanchard JF. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol. 2011; 106: 731-6.
152. Ardizzone S, Porro GB. How long is it advisable to prolong maintenance treatment of patients with ulcerative colitis? Inflamm Bowel Dis. 2008; 14 Suppl 2: S238-9.
153. Kamm MA. Review article: maintenance of remission in ulcerative colitis. Aliment Pharmacol Ther. 2002; 16 Suppl 4: 21-4.
154. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2): CD000544.